Skip to main content

Table 4 Multivariable regression analysis of postoperative AKI associated with parecoxib

From: Correlation between perioperative parecoxib use and postoperative acute kidney injury in patients undergoing radical mastectomy: a retrospective cohort analysis

AKI

Control

Parecoxib(40 or 80 mg)

Model 1

Model 2

Model 3

All cases

1

0.49 (0.27, 0.88) 0.017

0.48 (0.26, 0.87) 0.016

0.46 (0.24, 0.86) 0.015

EGFR < 90

1

0.58 (0.32, 1.04) 0.069

0.56 (0.31, 1.02) 0.058

0.52 (0.27, 0.97) 0.041

Blood loss < 1000 ml

1

0.52 (0.27, 1.00) 0.051

0.51 (0.27, 0.98) 0.045

0.48 (0.24, 0.96) 0.037

Non-diabetes

1

0.56 (0.30, 1.04) 0.066

0.54 (0.29, 1.01) 0.053

0.51 (0.26, 0.98) 0.045

AKI Stages

1

-0.04 (-0.07, -0.00) 0.030

-0.04 (-0.07, -0.00) 0.028

-0.04 (-0.07, -0.01) 0.013

  1. Model 1: Non-adjusted
  2. Model 2: Adjusted for age, BMI, alcohol consumption, anemia, hypertension, diabetes mellitus, ACEI, CCB, diuretics, ASA, anesthesia method, in fluids, out fluids, transfusion, and hemorrhage
  3. Model 3: Adjusted for model 2 plus ARB, preoperative eGFR, anesthesia method, operative time and intraoperative hypotension
Back to article page

BMC Anesthesiology

ISSN: 1471-2253

Contact us